NASDAQ$AURA
Aura Biosciences Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Aura Biosciences reported fiscal Q4 2026 (quarter ended March 31) with no revenue and a net loss of $33.7M, or $(0.50) per share.
For the three months ended March 31, 2026, Aura had no product revenue and operating expenses of $34.9 million, primarily R&D for bel-sar and AU-011 programs. Net loss was $33.7 million, or $(0.50) per share, compared with a $27.5 million loss and $(0.55) per share a year ago.
- Pre-revenue clinical-stage ocular oncology company.
- Net loss $33.7M; R&D $28.0M.
- Cash runway supports ongoing trials.
- Bel-sar pivotal programs advancing.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
Clinical trial progress and regulatory interactions on bel-sar will determine timeline to potential approval; no revenue expected near term.
Tailwinds
- Focused pipeline in ocular cancers.
- Loss per share slightly improved YoY.
Headwinds
- No revenue; cash burn continues.
- Clinical and regulatory execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2026
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro